Cargando…

Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study

INTRODUCTION: Atopic dermatitis (AD) can require long-term therapy. Few real-world studies have evaluated long-term effectiveness from the patients’ perspective. The aim of this study was to evaluate patient-reported outcomes (PROs) during long-term dupilumab treatment. METHODS: Adults with moderate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kimball, Alexa B., Delevry, Dimittri, Yang, Min, Chuang, Chien-Chia, Wang, Zhixiao, Bégo-Le-Bagousse, Gaëlle, Martins, Bruno, Wu, Eric, Shumel, Brad, Wang, Jessie, Sierka, Debra, Chao, Jingdong, Strober, Bruce
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442302/ https://www.ncbi.nlm.nih.gov/pubmed/37552431 http://dx.doi.org/10.1007/s13555-023-00965-5

Ejemplares similares

Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis
por: Yosipovitch, Gil, et al.
Publicado: (2021)

Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective
por: de Bruin-Weller, Marjolein, et al.
Publicado: (2021)

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
por: SILVERBERG, Jonathan I., et al.
Publicado: (2021)

Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset
por: Eichenfield, Lawrence F., et al.
Publicado: (2022)

Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
por: Kuznik, Andreas, et al.
Publicado: (2017)

Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use
por: DELEURAN, Mette, et al.
Publicado: (2021)

The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis
por: Kamal, Mohamed A., et al.
Publicado: (2021)

Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older
por: Simpson, Eric L., et al.
Publicado: (2021)

Dupilumab for atopic dermatitis
Publicado: (2019)

Impact of the Family and Household Environment on Pediatric Atopic Dermatitis in Japan
por: Saeki, Hidehisa, et al.
Publicado: (2023)

Development, Psychometric Validation and Responder Definition of Worst Itch Scale in Children with Severe Atopic Dermatitis
por: Paller, Amy S., et al.
Publicado: (2022)

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
por: Bansal, Ashish, et al.
Publicado: (2021)

Severe atopic dermatitis and dupilumab
por: Bernardo, Wanderley, et al.
Publicado: (2023)

Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023)

Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials
por: Silverberg, Jonathan I., et al.
Publicado: (2023)

Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial
por: Weyne, Jonathan, et al.
Publicado: (2020)

Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment
por: Armstrong, April, et al.
Publicado: (2021)

Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Publisher Correction to: Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials
por: Silverberg, Jonathan I., et al.
Publicado: (2023)

No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial
por: Wu, Jashin J., et al.
Publicado: (2021)

JAK-inhibitors as rescue therapy in dupilumab-refractory severe atopic dermatitis: A case series of 6 patients
por: Shahriari, Neda, et al.
Publicado: (2023)

Alopecia areata after dupilumab for atopic dermatitis
por: Mitchell, Krystal, et al.
Publicado: (2018)

Conjunctivitis in patients with atopic dermatitis treated with dupilumab
por: Ferreira, Sandra, et al.
Publicado: (2020)

Onychodystrophy associated with dupilumab therapy for atopic dermatitis
por: Zubek, Amanda E., et al.
Publicado: (2020)

Practical Management of Patients with Atopic Dermatitis on Dupilumab
por: Papp, Kim A., et al.
Publicado: (2021)

Improvement of atopic dermatitis and alopecia universalis with dupilumab
por: Alotaibi, Lama, et al.
Publicado: (2021)

Dupilumab in the Treatment of Cheilitis in Atopic Dermatitis Patients
por: Shan, Jinpeng, et al.
Publicado: (2022)

The evaluation of dupilumab treatment response in atopic dermatitis patients
por: Askin, Ozge, et al.
Publicado: (2020)

Dupilumab for the treatment of alopecia areata in children with atopic dermatitis
por: Cho, Sung Kyung, et al.
Publicado: (2021)

Definition of Clinically Meaningful Within-Patient Changes in POEM and CDLQI in Children 6 to 11 Years of Age with Severe Atopic Dermatitis
por: Simpson, Eric L., et al.
Publicado: (2021)

Efficacy and safety of dupilumab in Japanese adults with moderate‐to‐severe atopic dermatitis: a subanalysis of three clinical trials
por: Katoh, N., et al.
Publicado: (2019)

Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
por: WOLLENBERG, Andreas, et al.
Publicado: (2022)

Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis
por: Maudinet, Adrien, et al.
Publicado: (2019)

Effectiveness of Dupilumab in the treatment of both atopic dermatitis and alopecia universalis
por: Call, John E., et al.
Publicado: (2020)

Dupilumab-induced phenotype switching from atopic dermatitis to psoriasis
por: Varma, Aakaash, et al.
Publicado: (2020)

Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy
por: Peterson, Danielle M., et al.
Publicado: (2021)

Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis
por: Giavina-Bianchi, Mara, et al.
Publicado: (2021)

Long-term Remission of Atopic Dermatitis after Discontinuation of Dupilumab
por: MIYAMOTO, Shoko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l1l8or3vcjro2gi4m89ph1e20g